Log in

Antibe Therapeutics Stock Forecast, Price & News

-0.03 (-8.11 %)
(As of 10/21/2020 03:59 PM ET)
Today's Range
Now: C$0.34
50-Day Range
MA: C$0.36
52-Week Range
Now: C$0.34
Volume738,465 shs
Average Volume1.40 million shs
Market CapitalizationC$131.06 million
P/E RatioN/A
Dividend YieldN/A
Antibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent protected pharmaceuticals in Canada, Europe, and the United States. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, which has completed Phase IIB gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of cardiovascular disease and cancer chemoprevention. In addition, it offers various tissue regenerating products, such as bone grafting and dental membrane solutions for the dental and orthopedic markets; and surgical instruments for dental surgery, plastic surgery, general surgery and specialties, and veterinary applications. The company was incorporated in 2009 and is headquartered in Toronto, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.87 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesC$8.45 million
Cash FlowC$0.08 per share
Book ValueC$0.08 per share



Market CapC$131.06 million
Next Earnings Date11/26/2020 (Estimated)
OptionableNot Optionable
-0.03 (-8.11 %)
(As of 10/21/2020 03:59 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ATE News and Ratings via Email

Sign-up to receive the latest news and ratings for ATE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Antibe Therapeutics (CVE:ATE) Frequently Asked Questions

How has Antibe Therapeutics' stock been impacted by Coronavirus (COVID-19)?

Antibe Therapeutics' stock was trading at C$0.56 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ATE shares have decreased by 39.3% and is now trading at C$0.34.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Antibe Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antibe Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Antibe Therapeutics

When is Antibe Therapeutics' next earnings date?

Antibe Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 26th 2020.
View our earnings forecast for Antibe Therapeutics

How were Antibe Therapeutics' earnings last quarter?

Antibe Therapeutics Inc (CVE:ATE) released its quarterly earnings data on Monday, August, 24th. The company reported ($0.02) EPS for the quarter, hitting the Thomson Reuters' consensus estimate of ($0.02). The company earned $1.23 million during the quarter, compared to analysts' expectations of $2.25 million.
View Antibe Therapeutics' earnings history

What price target have analysts set for ATE?

3 Wall Street analysts have issued 1-year price targets for Antibe Therapeutics' stock. Their forecasts range from C$1.00 to C$1.50. On average, they anticipate Antibe Therapeutics' stock price to reach C$1.25 in the next year. This suggests a possible upside of 267.6% from the stock's current price.
View analysts' price targets for Antibe Therapeutics

Who are some of Antibe Therapeutics' key competitors?

What other stocks do shareholders of Antibe Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Antibe Therapeutics investors own include Resverlogix (RVX), Terra Tech (TRTC), Green Bancorp (GNBC), Tesla (TSLA), Cartier Iron (CFE), Maxar Technologies (MAXR), Nemaska Lithium Inc. (NMX.TO) (NMX), Royal Bank of Canada (RY.TO) (RY), Scorpio Gold (SGN) and Cronos Group (CRON).

Who are Antibe Therapeutics' key executives?

Antibe Therapeutics' management team includes the following people:
  • Mr. Daniel Marcel Legault, Pres, CEO, Sec. & Director (Age 61)
  • Dr. John Lawrence Wallace, Founder, Chief Scientific Officer & Director (Age 62)
  • Mr. Alain Wilson MBA, Chief Financial Officer
  • Mr. Scott Curtis M.Eng, CFA, VP of Corp. Devel.
  • Dr. David James Vaughan Ph.D., Chief Devel. Officer (Age 69)

What is Antibe Therapeutics' stock symbol?

Antibe Therapeutics trades on the Canadian Venture Exchange (CVE) under the ticker symbol "ATE."

How do I buy shares of Antibe Therapeutics?

Shares of ATE and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade, and Charles Schwab.

What is Antibe Therapeutics' stock price today?

One share of ATE stock can currently be purchased for approximately C$0.34.

How big of a company is Antibe Therapeutics?

Antibe Therapeutics has a market capitalization of C$131.06 million and generates C$8.45 million in revenue each year. Antibe Therapeutics employs 37 workers across the globe.

What is Antibe Therapeutics' official website?

The official website for Antibe Therapeutics is www.antibethera.com.

How can I contact Antibe Therapeutics?

Antibe Therapeutics' mailing address is 15 Prince Arthur Ave, TORONTO, ON M5R 1B2, Canada. The company can be reached via phone at +1-905-5705103.

This page was last updated on 10/22/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.